FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3146069114> ?p ?o ?g. }

• W3146069114 endingPage "447" @default.
• W3146069114 startingPage "435" @default.
• W3146069114 abstract "Rearranged during transfection (<i>RET</i>) rearrangements occur in 1% to 2% of lung adenocarcinomas as well as other malignancies and are now established targets for tyrosine kinase inhibitors. We developed three novel <i>RET</i> fusion–positive (<i>RET</i>+) patient–derived cancer cell lines, CUTO22 [kinesin 5B (<i>KIF5B</i>)–<i>RET</i> fusion], CUTO32 (<i>KIF5B</i>-<i>RET</i> fusion), and CUTO42 (echinoderm microtubule-associated protein-like 4–<i>RET</i> fusion), to study RET signaling and response to therapy. We confirmed each of our cell lines expresses the RET fusion protein and assessed their sensitivity to RET inhibitors. We found that the CUTO22 and CUTO42 cell lines were sensitive to multiple RET inhibitors, whereas the CUTO32 cell line was >10-fold more resistant to three RET inhibitors. We discovered that our <i>RET</i>+ cell lines had differential regulation of the mitogen-activated protein kinase and phosphoinositide 3-kinase/protein kinase B (AKT) pathways. After inhibition of RET, the CUTO42 cells had robust inhibition of phosphorylated AKT (pAKT), whereas CUTO22 and CUTO32 cells had sustained AKT activation. Next, we performed a drug screen, which revealed that the CUTO32 cells were sensitive (<1 nM IC₅₀) to inhibition of two cell cycle–regulating proteins, polo-like kinase 1 and Aurora kinase A. Finally, we show that two of these cell lines, CUTO32 and CUTO42, successfully establish xenografted tumors in nude mice. We demonstrated that the RET inhibitor BLU-667 was effective at inhibiting tumor growth in CUTO42 tumors but had a much less profound effect in CUTO32 tumors, consistent with our in vitro experiments. These data highlight the utility of new <i>RET+</i> models to elucidate differences in response to tyrosine kinase inhibitors and downstream signaling regulation. Our <i>RET+</i> cell lines effectively recapitulate the interpatient heterogeneity observed in response to RET inhibitors and reveal opportunities for alternative or combination therapies. <h3>SIGNIFICANCE STATEMENT</h3> We have derived and characterized three novel rearranged during transfection (RET) fusion non-small cell lung cancer cell lines and demonstrated that they have differential responses to RET inhibition as well as regulation of downstream signaling, an area that has previously been limited by a lack of diverse cell line modes with endogenous RET fusions. These data offer important insight into regulation of response to RET tyrosine kinase inhibitors and other potential therapeutic targets." @default.
• W3146069114 created "2021-04-13" @default.
• W3146069114 creator A5004389580 @default.
• W3146069114 creator A5006968359 @default.
• W3146069114 creator A5012452779 @default.
• W3146069114 creator A5019556057 @default.
• W3146069114 creator A5022348436 @default.
• W3146069114 creator A5033144024 @default.
• W3146069114 creator A5034705456 @default.
• W3146069114 creator A5040559928 @default.
• W3146069114 creator A5044209225 @default.
• W3146069114 creator A5075361012 @default.
• W3146069114 creator A5077285156 @default.
• W3146069114 date "2021-04-01" @default.
• W3146069114 modified "2023-09-27" @default.
• W3146069114 title "Novel Human-Derived <i>RET</i> Fusion NSCLC Cell Lines Have Heterogeneous Responses to RET Inhibitors and Differential Regulation of Downstream Signaling" @default.
• W3146069114 cites W1875361486 @default.
• W3146069114 cites W1964429855 @default.
• W3146069114 cites W1967887308 @default.
• W3146069114 cites W1975776530 @default.
• W3146069114 cites W1990013637 @default.
• W3146069114 cites W1990626198 @default.
• W3146069114 cites W1998284666 @default.
• W3146069114 cites W1998971866 @default.
• W3146069114 cites W2010457001 @default.
• W3146069114 cites W2024811932 @default.
• W3146069114 cites W2040317578 @default.
• W3146069114 cites W2057936106 @default.
• W3146069114 cites W2063252903 @default.
• W3146069114 cites W2065620201 @default.
• W3146069114 cites W2065799563 @default.
• W3146069114 cites W2073838595 @default.
• W3146069114 cites W2093613683 @default.
• W3146069114 cites W2096735709 @default.
• W3146069114 cites W2099530756 @default.
• W3146069114 cites W2116151820 @default.
• W3146069114 cites W2132578211 @default.
• W3146069114 cites W2146512944 @default.
• W3146069114 cites W2168404690 @default.
• W3146069114 cites W2169456326 @default.
• W3146069114 cites W2205646851 @default.
• W3146069114 cites W2293025578 @default.
• W3146069114 cites W2326198834 @default.
• W3146069114 cites W2409383155 @default.
• W3146069114 cites W2467902526 @default.
• W3146069114 cites W2523818766 @default.
• W3146069114 cites W2547299751 @default.
• W3146069114 cites W2576845640 @default.
• W3146069114 cites W2585352231 @default.
• W3146069114 cites W2600348349 @default.
• W3146069114 cites W2612352201 @default.
• W3146069114 cites W2624310346 @default.
• W3146069114 cites W2655216406 @default.
• W3146069114 cites W2752135966 @default.
• W3146069114 cites W2770828094 @default.
• W3146069114 cites W2785110924 @default.
• W3146069114 cites W2794472180 @default.
• W3146069114 cites W2796923356 @default.
• W3146069114 cites W2797098362 @default.
• W3146069114 cites W2800393195 @default.
• W3146069114 cites W2805346544 @default.
• W3146069114 cites W2885289995 @default.
• W3146069114 cites W2891362051 @default.
• W3146069114 cites W2894066036 @default.
• W3146069114 cites W2901045644 @default.
• W3146069114 cites W2901591386 @default.
• W3146069114 cites W2903070445 @default.
• W3146069114 cites W2905492903 @default.
• W3146069114 cites W2909291903 @default.
• W3146069114 cites W2947738455 @default.
• W3146069114 cites W3037804424 @default.
• W3146069114 cites W3081278682 @default.
• W3146069114 cites W3112101344 @default.
• W3146069114 doi "https://doi.org/10.1124/molpharm.120.000207" @default.
• W3146069114 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33795352" @default.
• W3146069114 hasPublicationYear "2021" @default.
• W3146069114 type Work @default.
• W3146069114 sameAs 3146069114 @default.
• W3146069114 citedByCount "5" @default.
• W3146069114 countsByYear W31460691142022 @default.
• W3146069114 countsByYear W31460691142023 @default.
• W3146069114 crossrefType "journal-article" @default.
• W3146069114 hasAuthorship W3146069114A5004389580 @default.
• W3146069114 hasAuthorship W3146069114A5006968359 @default.
• W3146069114 hasAuthorship W3146069114A5012452779 @default.
• W3146069114 hasAuthorship W3146069114A5019556057 @default.
• W3146069114 hasAuthorship W3146069114A5022348436 @default.
• W3146069114 hasAuthorship W3146069114A5033144024 @default.
• W3146069114 hasAuthorship W3146069114A5034705456 @default.
• W3146069114 hasAuthorship W3146069114A5040559928 @default.
• W3146069114 hasAuthorship W3146069114A5044209225 @default.
• W3146069114 hasAuthorship W3146069114A5075361012 @default.
• W3146069114 hasAuthorship W3146069114A5077285156 @default.
• W3146069114 hasBestOaLocation W31460691141 @default.
• W3146069114 hasConcept C101544691 @default.
• W3146069114 hasConcept C104317684 @default.
• W3146069114 hasConcept C123894998 @default.
• W3146069114 hasConcept C153911025 @default.

• next